Francisella Tularensis Infections - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 37 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Francisella Tularensis Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Francisella Tularensis Infections - Pipeline Review, H2 2014', provides an overview of the Francisella Tularensis Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Francisella Tularensis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Francisella Tularensis Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Francisella Tularensis Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Francisella Tularensis Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Francisella Tularensis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Francisella Tularensis Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Francisella Tularensis Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Francisella Tularensis Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Francisella Tularensis Infections Overview 6
Therapeutics Development 7
Pipeline Products for Francisella Tularensis Infections - Overview 7
Pipeline Products for Francisella Tularensis Infections - Comparative Analysis 8
Francisella Tularensis Infections - Therapeutics under Development by Companies 9
Francisella Tularensis Infections - Therapeutics under Investigation by Universities/Institutes 10
Francisella Tularensis Infections - Pipeline Products Glance 11
Early Stage Products 11
Francisella Tularensis Infections - Products under Development by Companies 12
Francisella Tularensis Infections - Products under Investigation by Universities/Institutes 13
Francisella Tularensis Infections - Companies Involved in Therapeutics Development 14
Aradigm Corporation 14
Evolva SA 15
Francisella Tularensis Infections - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
ciprofloxacin hydrochloride - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
EV-009 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
francisella tularensis [strain SchuS4] vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
francisella tularensis vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
HB-19 Analogues - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibodies to Inhibit EF-Tu for Francisella Tularensis Infections - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule to Inhibit Enoyl-Reductase for Bacillus Anthracis and Francisella Tularensis Infections - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Inhibit FtsZ Protein for Bacterial Infections - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Francisella Tularensis Infections - Dormant Projects 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Number of Products under Development for Francisella Tularensis Infections, H2 2014 7
Number of Products under Development for Francisella Tularensis Infections - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Products under Investigation by Universities/Institutes, H2 2014 13
Francisella Tularensis Infections - Pipeline by Aradigm Corporation, H2 2014 14
Francisella Tularensis Infections - Pipeline by Evolva SA, H2 2014 15
Assessment by Monotherapy Products, H2 2014 16
Number of Products by Stage and Target, H2 2014 18
Number of Products by Stage and Mechanism of Action, H2 2014 20
Number of Products by Stage and Route of Administration, H2 2014 22
Number of Products by Stage and Molecule Type, H2 2014 24
Francisella Tularensis Infections - Dormant Projects, H2 2014 35